Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Breast Neoplasms
Clinical trial register · Italy

Breast Neoplasms Trials in Italy, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6779 matching records held by the registry are in this view. Synced 10 Nov 2026, 03:19 UTC
6779
Studies in scope
all four open statuses
4070
Recruiting now
open to new participants
1013
Lead sponsors
across recruiting studies
Top sites
Milan 15 Naples 8 Roma 8 Bologna 6 Meldola 5

Breast Neoplasms trials in Italy

24 of 6779 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Not yet open
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Observational
200,075
Rome
2026-11-01
Recruiting
Eli Lilly and Company
Phase 2
600
Genova, Milan, Misterbianco, Prato, Roma
2026-05-13
Recruiting
Eli Lilly and Company
Phase 3
800
Bergamo, Bologna, Florence, Genova, Meldola, Milan, Misterbianco, Monza
2025-12-22
Recruiting
BioNTech SE
Phase 3
558
Aviano, Lucca, Milan, Monza, Pisa, Roma, Siena, Torrette
2025-10-30
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Bergamo, Milan, Naples, Roma
2025-07-21
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
2,400
Monza, Livorno, Ancona, Bergamo, Genova, Milan, Padova, Pisa
2025-06-30
Active, closed
Pfizer
Phase 1/2
74
Naples, Meldola, Aviano, Livorno, Roma
2025-06-30
Active, closed
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
54
Naples, Milan, Misterbianco (CT), Verona
2024-05-20
Recruiting
Fondazione Policlinico Universitario Campus Bio-Medico
Not applicable
155
Roma
2023-05-15
Recruiting
Breast Cancer and Resilience in Couple
NCT06875414Breast Neoplasms, Quality of Life
Regina Elena Cancer Institute
Observational
40
Roma
2022-11-14
Active, closed
Eli Lilly and Company
Phase 3
8,000
Ancona, Bergamo, Bologna, Brindisi, Candiolo, Florence, Genova, Milan
2022-10-04
Recruiting
Stemline Therapeutics, Inc.
Phase 1/2
73
Ancona, Candiolo, Meldola, Messina, Milan, Modena, Monza, Naples
2022-08-31
Active, closed
Regina Elena Cancer Institute
Phase 2
180
Rome
2022-02-01
Active, closed
AstraZeneca
Phase 3
927
Bologna, Candiolo, Livorno, Milan, Naples, Negrar, Padova, Roma
2021-10-25
Active, closed
Tethis S.p.A.
Observational
84
Milan
2021-10-04
Active, closed
Eli Lilly and Company
Phase 3
874
Naples, Aviano, Rome, Genoa, Florence, Padova
2021-10-04
Active, closed
Merck Sharp & Dohme LLC
Phase 3
342
Rome, Milan, Monza, Rozzano, Bari, Catania, Naples, Padova
2021-06-18
Recruiting
GlaxoSmithKline
Phase 2
37
Cremona
2021-04-16
Active, closed
Eli Lilly and Company
Phase 3
669
Cona, Rome, Bologna, Padova
2014-07-22
Recruiting
PREgnancy and FERtility Registry
NCT02895165Breast Neoplasms, Pregnancy, Fertility Preservation
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Observational
1,000
Asti, Brindisi, Monserrato, Cuneo, Cona, Genoa, Lecce, Lido di Camaiore
2012-11
Active, closed
Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up
NCT01357772Carcinoma, Intraductal, Noninfiltrating, Recurrence, Local Neoplasm, Breast Neoplasms, Atypical Hyperplasia
Andrea DeCensi
Phase 3
500
Tortona, Meldola, Carpi, Bari, Catanzaro, Genoa, Milan, Modena
2008-11-12
Recruiting
Establishment of a Tumor Bank for Blood Samples
NCT01763125Ovarian Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Neoplasms of the Female Genitalia
Medical University of Vienna
Observational
10,000
Milan
2003-11
Rows per page Showing 1–24 of 24
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 November 2026. https://priyalifescience.com/clinical-trials-italy/condition/breast-neoplasms

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,779 studies in total at the last sync on 10 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 24 of those studies listing the condition Breast Neoplasms.

How many Breast Neoplasms trials are recruiting in Italy?

13 of the 24 studies on this page are recruiting new participants as of the 10 Nov 2026, 03:19 UTC sync. A further 1 have not yet opened recruitment, 10 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Breast Neoplasms), 24 studies
PhaseStudiesRecruitingShare
Phase 311545.8%
Observational5320.8%
Phase 24216.7%
Phase 1/2218.3%
Not applicable114.2%
Phase 2/3114.2%

Most active sponsors

Lead sponsors with the most studies (Breast Neoplasms)
Lead sponsorStudiesRecruiting
Eli Lilly and Company52
Merck Sharp & Dohme LLC43
Regina Elena Cancer Institute21
Andrea DeCensi10
AstraZeneca10
BioNTech SE11
Bristol-Myers Squibb11
Fondazione Policlinico Universitario Agostino Gemelli IRCCS10
Fondazione Policlinico Universitario Campus Bio-Medico11
GlaxoSmithKline11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.